Uncategorized

Darzalex Combo Extends Survival in Newly Diagnosed Myeloma Patients, Phase 3 Trial Shows — Myeloma Research News

Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients who are not eligible for an autologous stem cell transplant, a Phase 3 clinical trial shows. Findings from the MAIA trial (NCT02252172) were published in The New England Journal of Medicine in the study, “Daratumumab…

via Darzalex Combo Extends Survival in Newly Diagnosed Myeloma Patients, Phase 3 Trial Shows — Myeloma Research News

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: